Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.

April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
Copyright © Ark Medical Solutions Inc. All Rights Reserved.